Boulder Imaging Powers First CDI2-Compliant Technology for Central Banks 12-02-2025, 16:00

RPT Realty to Present at Citi’s 2023 Global Property CEO 3-03-2023, 04:23

Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26